ArticleCureus2025
Delayed-Onset Immune-Mediated Hepatitis Following Pembrolizumab Discontinuation: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review.Rambam Maimonides medical journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) such as pembrolizumab (Keytruda) have transformed the treatment landscape for various malignancies, yet they are associated with immune-related adverse events (irAEs), including hepatotoxicity. While most cases of ICI-induced hepatitis occur within weeks of initiating therapy, delayed-onset presentations are increasingly recognized. We report a case of severe transaminase elevation developing three months after cessation of pembrolizumab in a patient with a history of gallbladder carcinoma. Her chemotherapy was placed on hold after a recent stroke led to a worsening functional status, with the initial intent to resume pembrolizumab once her functional status normalized. Workup excluded infectious, metabolic, and autoimmune causes. Liver biopsy revealed immune-mediated hepatitis with histologic evidence of only mild cholestasis. The patient responded to corticosteroid therapy, supporting the diagnosis of ICI-induced hepatotoxicity. This case underscores the importance of maintaining a high index of suspicion for immune-mediated liver injury well beyond the period of active immunotherapy and highlights the diagnostic value of liver biopsy in complex presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.